T1	Premise 42 275	A 78-year-old woman with a history of type 2 diabetes treated with oral antidiabetics, hypertension treated with beta-blockers and ACE inhibitors, and NYHA grade 1 congestive heart failure with LVEF of 48%, and currently asymptomatic
T2	Premise 277 302	Functional status: ECOG 0
T3	Premise 304 362	History of 2 years of evolution of small lumps in the neck
T4	Premise 364 422	Biopsy of cervical adenopathy: follicular lymphoma grade 2
T5	Premise 441 451	Hb 12 g/dL
T6	Premise 453 555	Leukocytes 6,900/microL (Neutrophils 60%, Lymphocytes 27%, Monocytes 6%, Eosinophils 4%, Basophils 4%)
T7	Premise 557 581	Platelets 220,000/microL
T8	Premise 583 620	MO: infiltrate by follicular lymphoma
T9	Premise 622 642	Creatinine 1.5 mg/dL
T10	Premise 644 655	LDH 235 U/L
T11	Premise 657 690	Beta2 microglobulin 2.1 microg/mL
T12	Premise 692 828	CT: lymphadenopathies less than 3 cm in cervical, axillary, retroperitoneal, iliac and inguinal territories; liver and spleen are normal
T13	Claim 892 962	Rituximab-CHOP (Cyclophosphamide, Adriamycin, Vincristine, Prednisone)
T14	Claim 967 1024	Rituximab-CVP (Cyclophosphamide, Vincristine, Prednisone)
T15	Claim 1029 1068	Do not treat and monitor (wait and see)
T16	Claim 1073 1096	Rituxirnab-Bendamustine
T17	Claim 1123 1222	There may be debate about whether to start Rituximab with another cytostatic drug or in monotherapy
T18	Claim 1228 1448	given the lack of survival benefit with early initiation of treatment, the NCCN guidelines recommend waiting and seeing, unless GELF criteria are met to initiate treatment: GELF criteria (Follicular Lymphoma Study Group)
T19	Marker 1224 1227	but
R1	Attack Ent1:T18 Ent2:T17	
R2	Support Ent1:T18 Ent2:T15	
T20	Treatment 892 906	Rituximab-CHOP
T21	Treatment 908 924	Cyclophosphamide
T22	Treatment 926 936	Adriamycin
T23	Treatment 938 949	Vincristine
T24	Treatment 951 961	Prednisone
T25	Treatment 967 980	Rituximab-CVP
T26	Treatment 982 998	Cyclophosphamide
T27	Treatment 1000 1011	Vincristine
T28	Treatment 1013 1023	Prednisone
T29	Treatment 1073 1096	Rituxirnab-Bendamustine
